Q4 2024 Senseonics Holdings Inc Earnings Call Transcript

Mar 3, 2025 / 09:30 PM GMT

Release Date Price: $17.4 (+2.35%)

Transcript 10-K8-K

Key Points

Positve

Senseonics Holdings Inc (SENS) successfully launched the Eversense 365, the world's first and only once-yearly continuous glucose monitor, in the US, receiving positive feedback from both providers and patients.
The company has filed for CE mark approval for Eversense 365 in Europe, with plans to launch in the European Union in the second half of 2025.
Patient base increased by 56% in 2024, surpassing the target growth of 50%, with a significant number of patients switching from competitive CGMs.
Gross profit increased significantly in Q4 2024, driven by increased margins on the 365-day product and reduced manufacturing costs.
Senseonics Holdings Inc (SENS) has strengthened its balance sheet by repaying convertible notes and converting preferred stock into common stock, extending its cash runway into mid-2026.

Negative

Net loss for 2024 increased by $18.2 million compared to 2023, primarily due to a reduction in gains from the exchange of existing notes and changes in the fair value of derivatives.
Total revenue for 2024 remained relatively flat compared to 2023, despite a significant increase in the patient base.
Revenue outside the US decreased from $8.3 million in 2023 to $7.2 million in 2024.
Research and development expenses, although decreased, still amounted to $41.1 million in 2024, reflecting ongoing high costs.
The company faces challenges in transitioning US reimbursement from Eversense E3 to Eversense 365, particularly in the Medicare segment, which could impact revenue growth.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SENS.A - Senseonics Holdings Inc
Q4 2024 Senseonics Holdings Inc Earnings Call
Mar 03, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Mm.

Good day everyone and welcome to today's Sensionics 4th quarter in full year 2024 earnings call. At this time, all participants are in a listen-only mode. Later you will have the opportunity to ask questions during the question and answer session.

Please note today's call will be recorded, and I will be standing by should you need any assistance.

It is now my pleasure to turn the conference over to Jeremy Pfeffer from Lifeci Advisors. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you. This is Jeremy Pfeffer from Life

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.